Relmada Therapeutics, Inc. (RLMD)
NASDAQ: RLMD · IEX Real-Time Price · USD
4.590
-0.100 (-2.13%)
Mar 27, 2024, 4:30 PM EDT - Market closed

Relmada Therapeutics Cash Flow Statement

Millions USD. Fiscal year is Jan - Dec.
Year 202320222021202020192018201720162015
Net Income
-98.79-157.04-125.75-59.46-15.01-8.96-6.29-2.97-20.8
Depreciation & Amortization
0000000.090.050.01
Share-Based Compensation
43.8144.1940.4920.783.170.520.71.211.98
Other Operating Activities
3.329.05-6.6210.87-0.262.44-0.97-11.432.59
Operating Cash Flow
-51.66-103.8-91.87-27.81-12.09-6-6.47-13.14-16.23
Capital Expenditures
00000-0.01-0.05-0.56-0.02
Change in Investments
50.4519.73-54.12-34.45-80.160000
Investing Cash Flow
50.4519.73-54.12-34.45-80.16-0.01-0.05-0.56-0.02
Share Issuance / Repurchase
043.43185.3120.53122.030000
Debt Issued / Paid
000-0.11-0.370.01-0.27-0.26-0.29
Other Financing Activities
-0.11.592.638.064.456.53--13.45
Financing Cash Flow
-0.145.02187.9428.47126.116.54-0.27-0.2613.16
Net Cash Flow
-1.3-39.0541.95-33.7833.850.53-6.79-13.97-3.09
Free Cash Flow
-51.66-103.8-91.87-27.81-12.09-6.01-6.52-13.71-16.25
Free Cash Flow Per Share
-1.72-3.50-5.23-1.78-1.31-1.92-2.16-4.73-6.54
Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).